<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756921</url>
  </required_header>
  <id_info>
    <org_study_id>YOUNGBC-13</org_study_id>
    <nct_id>NCT04756921</nct_id>
  </id_info>
  <brief_title>18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response</brief_title>
  <official_title>Pretreatment 18F-FDG Uptake Heterogeneity Predicts Response to Pyrotinib in Patients With Metastatic HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biyun Wang, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting&#xD;
      response to treatment. This study aimed to evaluate the ability of pretreatment positron&#xD;
      emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the&#xD;
      response to pyrotinib in patients with human epidermal growth factor receptor 2&#xD;
      (HER2)-positive metastatic breast cancer (MBC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">July 24, 2020</completion_date>
  <primary_completion_date type="Actual">July 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Through study completion, an expected average of 12 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients cohort</arm_group_label>
    <description>Patients with HER2 positive MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Pyrotinib 400mg po qd</description>
    <arm_group_label>Patients cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with HER2 positive breast cancer with confirmed metastasis, regardless&#xD;
        of being de novo diagnosed or progressed from a non-metastatic stage.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed HER2 positive breast cancer&#xD;
&#xD;
          -  Treated with Pyrotinib in the metastatic settings&#xD;
&#xD;
          -  Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and&#xD;
             capecitabine were included in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incomplete medical history&#xD;
&#xD;
          -  Loss of follow up&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Biyun Wang, MD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

